HRP20040243B1 - Cross-linked glycopeptide-cephalosporin antibiotics - Google Patents

Cross-linked glycopeptide-cephalosporin antibiotics

Info

Publication number
HRP20040243B1
HRP20040243B1 HR20040243A HRP20040243A HRP20040243B1 HR P20040243 B1 HRP20040243 B1 HR P20040243B1 HR 20040243 A HR20040243 A HR 20040243A HR P20040243 A HRP20040243 A HR P20040243A HR P20040243 B1 HRP20040243 B1 HR P20040243B1
Authority
HR
Croatia
Prior art keywords
group
independently selected
optionally substituted
6alkyl
heteroaryl
Prior art date
Application number
HR20040243A
Other languages
English (en)
Croatian (hr)
Inventor
Fatheree Paul
S. Linsell Martin
D. Long Daniel
Marquess Daniel
J. Moran Edmound
B. Nodwell Matthew
S. Turner Derek
Aggen James
Original Assignee
Theravance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance filed Critical Theravance
Publication of HRP20040243A2 publication Critical patent/HRP20040243A2/hr
Publication of HRP20040243B1 publication Critical patent/HRP20040243B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HR20040243A 2001-10-12 2004-03-12 Cross-linked glycopeptide-cephalosporin antibiotics HRP20040243B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32888901P 2001-10-12 2001-10-12
PCT/US2002/032534 WO2003031449A2 (en) 2001-10-12 2002-10-11 Cross-linked glycopeptide-cephalosporin antibiotics

Publications (2)

Publication Number Publication Date
HRP20040243A2 HRP20040243A2 (en) 2004-08-31
HRP20040243B1 true HRP20040243B1 (en) 2008-07-31

Family

ID=23282891

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040243A HRP20040243B1 (en) 2001-10-12 2004-03-12 Cross-linked glycopeptide-cephalosporin antibiotics

Country Status (30)

Country Link
US (11) US6974797B2 (xx)
EP (1) EP1434779B1 (xx)
JP (3) JP4249023B2 (xx)
KR (1) KR100888660B1 (xx)
CN (2) CN1329397C (xx)
AT (1) ATE314376T1 (xx)
AU (1) AU2002332111B2 (xx)
BR (2) BR0213154A (xx)
CA (1) CA2463544C (xx)
CO (1) CO5580782A2 (xx)
DE (1) DE60208404T2 (xx)
DK (1) DK1434779T3 (xx)
EA (1) EA007001B1 (xx)
ES (1) ES2254738T3 (xx)
HK (1) HK1066007A1 (xx)
HR (1) HRP20040243B1 (xx)
HU (1) HU230158B1 (xx)
IL (2) IL160846A0 (xx)
IS (1) IS2422B (xx)
MX (1) MXPA04003273A (xx)
NO (1) NO334092B1 (xx)
NZ (1) NZ531576A (xx)
PL (1) PL209757B1 (xx)
RS (1) RS50888B (xx)
SI (1) SI1434779T1 (xx)
SK (1) SK2052004A3 (xx)
TW (1) TWI335332B (xx)
UA (1) UA80098C2 (xx)
WO (1) WO2003031449A2 (xx)
ZA (1) ZA200402732B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
TWI325323B (en) 2002-05-24 2010-06-01 Theravance Inc Cross-linked glycopeptide-cephalosporin antibiotics
DE602004024393D1 (de) * 2003-05-23 2010-01-14 Theravance Inc Quervernetzte glycopeptid-cephalosporin-antibiotika
WO2005005436A2 (en) * 2003-07-11 2005-01-20 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
KR100808414B1 (ko) * 2004-06-08 2008-02-29 엘지전자 주식회사 이동단말의 클라이언트 세션 복구방법
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
JP6151257B2 (ja) 2011-09-09 2017-06-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 肺内感染症の治療方法
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CA2902724A1 (en) * 2013-03-13 2014-10-09 Theravance Biopharma Antibiotics Ip, Llc Crystalline form of a substituted thiazolylacetic acid triethylamine salt
PT2968446T (pt) * 2013-03-13 2017-07-27 Theravance Biopharma Antibiotics Ip Llc Sais cloridrato de um composto antibiótico
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3100732A1 (en) 2013-03-15 2016-12-07 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US10943049B2 (en) * 2018-09-28 2021-03-09 Taiwan Semiconductor Manufacturing Co., Ltd. Rule check violation prediction systems and methods
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693791A (en) * 1995-04-11 1997-12-02 Truett; William L. Antibiotics and process for preparation
WO1999042476A1 (en) * 1998-02-20 1999-08-26 Advanced Medicine, Inc. Novel antibacterial agents
WO1999064049A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel antibacterial agents
WO2000039156A1 (en) * 1998-12-23 2000-07-06 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US457926A (en) * 1891-08-18 Steam-engine
US4668783A (en) * 1974-12-19 1987-05-26 Takeda Chemical Industries, Ltd. Thiazolylacetamido cephalosporin compounds
FR2347706A1 (fr) * 1976-04-08 1977-11-04 Issec Labo Physicochimie Appli Nouveau procede photographique d'impression en couleurs sur divers substrats
JPS5994B2 (ja) * 1976-09-14 1984-01-05 富士写真フイルム株式会社 感光性組成物
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
DE2758001A1 (de) 1977-12-24 1979-07-12 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
US4284631A (en) 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
DE3006888A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4427677A (en) * 1980-12-31 1984-01-24 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE3118732A1 (de) * 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS5859991A (ja) * 1981-09-14 1983-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
US4427877A (en) * 1981-09-28 1984-01-24 Raychem Corporation Printing on low surface energy polymers
DE3207840A1 (de) * 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
DE3316798A1 (de) * 1983-05-07 1984-11-08 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von cephemverbindungen
JPS6041682A (ja) 1983-08-16 1985-03-05 Meiji Seika Kaisha Ltd 新規セフアロスポリン化合物及びその製造法
DE3418482A1 (de) * 1984-05-18 1985-11-21 Basf Ag, 6700 Ludwigshafen Magnetische aufzeichnungstraeger
US4840945A (en) * 1985-04-01 1989-06-20 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
US4921851A (en) 1986-06-09 1990-05-01 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
US4974797A (en) * 1988-03-17 1990-12-04 Consolidated Rail Corporation Hot bearing simulator
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
AUPN955596A0 (en) * 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
JP3906938B2 (ja) * 1997-02-18 2007-04-18 富士フイルム株式会社 画像再生方法及び画像データ管理方法
US6437119B1 (en) 1998-05-07 2002-08-20 William Lawrence Truett Compounds formed from two or three antibiotics and their processes of preparation
WO2000064049A1 (en) 1999-04-19 2000-10-26 Attila Lenkehegyi Dually adjustable electromechanical means for handling and system of these, and dually adjustable digital potentiometer
US20070154948A1 (en) 1999-05-24 2007-07-05 Christensen Burton G Novel antibacterial agents
AU2001246399A1 (en) 2000-04-06 2001-10-23 Maersk Medical A/S A coupling arrangement
JP4107792B2 (ja) * 2000-08-28 2008-06-25 独立行政法人科学技術振興機構 可視光応答性を有する金属オキシナイトライドからなる光触媒
US6885138B1 (en) * 2000-09-20 2005-04-26 Samsung Electronics Co., Ltd. Ferroelectric emitter
US7087482B2 (en) * 2001-01-19 2006-08-08 Samsung Electronics Co., Ltd. Method of forming material using atomic layer deposition and method of forming capacitor of semiconductor device using the same
US20030009681A1 (en) * 2001-07-09 2003-01-09 Shunji Harada Digital work protection system, recording medium apparatus, transmission apparatus, and playback apparatus
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
TWI325323B (en) * 2002-05-24 2010-06-01 Theravance Inc Cross-linked glycopeptide-cephalosporin antibiotics
DE602004024393D1 (de) 2003-05-23 2010-01-14 Theravance Inc Quervernetzte glycopeptid-cephalosporin-antibiotika
WO2005005436A2 (en) 2003-07-11 2005-01-20 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
CN100352223C (zh) * 2004-12-31 2007-11-28 华为技术有限公司 一种在城域传输网络中保护数据业务的方法
US8101791B2 (en) 2007-12-11 2012-01-24 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693791A (en) * 1995-04-11 1997-12-02 Truett; William L. Antibiotics and process for preparation
WO1999042476A1 (en) * 1998-02-20 1999-08-26 Advanced Medicine, Inc. Novel antibacterial agents
WO1999064049A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel antibacterial agents
WO2000039156A1 (en) * 1998-12-23 2000-07-06 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
US20050239691A1 (en) 2005-10-27
NO334092B1 (no) 2013-12-09
SI1434779T1 (sl) 2006-06-30
KR100888660B1 (ko) 2009-03-13
US20080108558A1 (en) 2008-05-08
EP1434779A2 (en) 2004-07-07
US6974797B2 (en) 2005-12-13
CN1329397C (zh) 2007-08-01
US20100197569A1 (en) 2010-08-05
HUP0401596A2 (hu) 2004-12-28
IL160846A (en) 2010-05-17
DE60208404D1 (de) 2006-02-02
JP2009143962A (ja) 2009-07-02
RS50888B (sr) 2010-08-31
US20080194465A1 (en) 2008-08-14
PL209757B1 (pl) 2011-10-31
EA200400530A1 (ru) 2004-08-26
ES2254738T3 (es) 2006-06-16
US7649080B2 (en) 2010-01-19
CN1781916A (zh) 2006-06-07
CA2463544C (en) 2011-03-29
DE60208404T2 (de) 2006-07-27
CN1568325A (zh) 2005-01-19
ATE314376T1 (de) 2006-01-15
US20080039611A1 (en) 2008-02-14
IL160846A0 (en) 2004-08-31
US7601690B2 (en) 2009-10-13
NZ531576A (en) 2006-10-27
HUP0401596A3 (en) 2013-06-28
HRP20040243A2 (en) 2004-08-31
US7553962B2 (en) 2009-06-30
US20080194464A1 (en) 2008-08-14
CA2463544A1 (en) 2003-04-17
TWI335332B (en) 2011-01-01
WO2003031449A2 (en) 2003-04-17
CO5580782A2 (es) 2005-11-30
BR0213154A (pt) 2004-08-10
IS7172A (is) 2004-03-04
US7713931B2 (en) 2010-05-11
US8557978B2 (en) 2013-10-15
US7612037B2 (en) 2009-11-03
US20120214967A1 (en) 2012-08-23
ZA200402732B (en) 2005-05-25
NO20041912L (no) 2004-05-10
US20080039374A1 (en) 2008-02-14
MXPA04003273A (es) 2004-07-08
CN100358901C (zh) 2008-01-02
US7655621B2 (en) 2010-02-02
US20080051577A1 (en) 2008-02-28
HK1066007A1 (en) 2005-03-11
YU29504A (sh) 2006-08-17
US7728127B2 (en) 2010-06-01
US8044195B2 (en) 2011-10-25
JP4445028B2 (ja) 2010-04-07
SK2052004A3 (en) 2004-10-05
IS2422B (is) 2008-10-15
KR20050035122A (ko) 2005-04-15
PL368451A1 (en) 2005-03-21
EP1434779B1 (en) 2005-12-28
HU230158B1 (hu) 2015-09-28
EA007001B1 (ru) 2006-06-30
US20030130173A1 (en) 2003-07-10
UA80098C2 (en) 2007-08-27
AU2002332111B2 (en) 2008-04-17
US20080045721A1 (en) 2008-02-21
JP2009040795A (ja) 2009-02-26
BRPI0213154B1 (pt) 2018-01-16
WO2003031449A3 (en) 2003-08-28
JP4249023B2 (ja) 2009-04-02
JP2005507907A (ja) 2005-03-24
US7341993B2 (en) 2008-03-11
DK1434779T3 (da) 2006-01-30

Similar Documents

Publication Publication Date Title
HRP20040243B1 (en) Cross-linked glycopeptide-cephalosporin antibiotics
AR047848A1 (es) Analogos de rifamicina y composiciones farmaceuticas que los contienen.
DK1258484T3 (da) Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR019789A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
NO902214D0 (no) Fremgangsmaate for fremstilling av n-(aryloksyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner og deres anvendelse som medikamenter.
HRP20080236T3 (en) Quinoline derivatives as phosphodiesterase inhibitors
FI901030A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia 2-(1-piperatsinyyli)-4-fenyylisykloalkanopyridiinijohdannaisia
AR032621A1 (es) Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
AR030279A1 (es) Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos.
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR016789A1 (es) Compuestos derivados de bencilideno-1,3-dihidro-indol-2-ona que tienen actividad anticancer, composiciones farmaceuticas, proceso para su preparacion
AR011101A1 (es) Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene
GB1046506A (en) Guanidine compounds and process for their manufacture
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
SE9703377D0 (sv) New compounds
MEP21308A (en) Ryl alkyl carbamate derivatives production and use thereof in therapy
AR059329A1 (es) Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion
DE60024471D1 (de) Benzopyran derivate
AR066603A1 (es) Derivados de arilamida pirimidona
PE20030705A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20180921

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20191011